[2] In 1999, patients with chronic angina who were admitted to hospitals for diagnostic procedures or therapy incurred a direct cost of more than $7.5 billion. Assuming non-Medicare patients ...

In January 2006, the U.S. Food and Drug Administration (FDA) approved a new antianginal agent for the treatment of chronic stable angina, ranolazine (Ranexa™; CV Therapeutics, Inc.). The drug ...

The primary symptoms of occlusive CAD include chronic stable angina pectoris. Substernal chest pressure upon physical exertion with radiation to the medial portion of the left arm or left jaw is ...

and delays the development of ischemia in patients with chronic stable angina being treated with atenolol. Ivabradine should be considered in the medical management of symptom-limited patients ...

whereas a non-STEMI results in myocyte necrosis with detectable enzyme abnormalities The symptoms of occlusive coronary artery disease can manifest as chronic stable angina pectoris or angina as a ...

To reduce combined risk of death and nonfatal MI after MI or unstable angina pectoris. To reduce combined risk of MI and sudden death in chronic stable angina. Revascularization procedures.

A new study published this week in Child Maltreatment found that in comparison to those who had not been abused in childhood, adults who had experienced both childhood physical and sexual abuse had ...

To reduce combined risk of death and nonfatal MI after MI or unstable angina pectoris. To reduce combined risk of MI and sudden death in chronic stable angina. Revascularization procedures.